Early Data In Hand, Vesper Bio Takes On GSK And Alector

 
• By Elizabeth Cairns

Emerging Company Profile: Danish group Vesper Bio is advancing an oral sortilin inhibitor in frontotemporal dementia, and is aiming to get to market in a similar timeframe to its much larger rivals.    

Memory loss and brain aging due to dementia and alzheimer's disease as a medical icon of a group of color changing autumn fall trees shaped as a human head losing leaves on a white background.

More from Emerging Company Profiles

More from Leadership